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Abstract
Background: The 1858C/T SNP of the PTPN22 gene has been associated with many autoimmune
diseases, suggesting the existence of an inflammatory process common to all of them. We studied
the association of that polymorphism with immunoglobulin A deficiency (IgAD) following a double
approach: a case-control and a TDT study.
Methods: A total of 259 IgAD patients and 455 unrelated matched controls, and 128 families were
used for each approach. Comparisons were performed using Chi-Square tests or Fisher's exact test
when necessary.
Results: No association between the PTPN22 1858C/T SNP and IgA deficiency was found in any
case (allelic frequencies 8% vs. 6% in patients and controls, respectively, OR= 1.14 (0.72–1.79), p=
0.56; TDT p = 0.08).
Conclusion: The result obtained seems to reinforce the consideration of IgA deficiency as a
primary immunodeficiency rather than an autoimmune disease.
Background
Selective IgA deficiency (IgAD) is the most prevalent pri-
mary immunodeficiency in white populations, with val-
ues around one out of 600 [1]. This disease is
characterized by a severe deficiency or total absence of IgA
class immunoglobulins in the serum and secretions. Their
clinical symptoms are very variable, and thus some IgAD
patients are relatively healthy while others show signifi-
cant illness, mainly a higher susceptibility to infections,
autoimmune diseases and allergies. IgAD shows a multi-
factorial origin, with genetic and environmental factors
involved. Class II and class III HLA genes have been impli-
cated in the origin of this disease (see [2] and references
therein). However, these HLA genetic components can
not explain the totality of the genetic influence in this dis-
ease.
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The molecular bases underlying the origin of IgAD are not
completely understood. Although it has been recently
shown that a mutation in TACI is involved in the origin of
the disease in some patients [3], other genetic and envi-
ronmental factors remain to be discovered. Despite IgAD
has been traditionally considered as an immunodefi-
ciency, some authors [4] have pointed out that it could be
an autoimmune disease.
Recently, a single-nucleotide polymorphism (SNP) of the
PTPN22 (protein tyrosine phosphatase, non-receptor type
22) gene, 1858C/T, has been found associated with many
autoimmune diseases [5,6]. This gene, located on chro-
mosome 1p13, encodes a lymphoid protein tyrosine
phosphatase (PTP Lyp) involved in the regulation of the
T-cell receptor signaling pathway. The 1858C/T SNP
results in an amino-acid change that alters the function of
the PTP Lyp. The allele 1858T originates an altered protein
unable to inhibit T-cell responses, what would imply a
pathogenic response.
The aim of this work is to study the association of the
1858C/T polymorphism of the PTPN22 gene with IgAD
and to deepen in its implication concerning the contro-
versial origin of this disease.
Methods
Subjects
We studied a total of 259 white patients with IgAD as
defined by the World Health Organization Group on Pri-
mary Immunodeficiencies (<0.05 g/L [7]), recruited from
a single Spanish Centre (Hospital La Paz, Madrid) and
455 unrelated matched healthy controls obtained from
blood donors at the Hospital Clínico San Carlos
(Madrid). One hundred and twenty-eight families com-
posed of the affected subject and their parents were also
included in the study. Informed consent was obtained
from all the participants. This study was approved by the
Ethics Committee of the Hospital Clínico San Carlos.
Genotyping
All the individuals included in the study were typed for
the PTPN22 1858C/T (rs2476601) variant using a Taq-
Man 5' allelic discrimination Assay-By-Design method
(Applied Biosystems, Norwalk, USA).
HLA typing was performed as previously described [2].
Statistical analysis
Allelic frequencies and carriage rates were compared
between cases and controls by means of chi-square tests or
Fisher's exact test when necessary (expected values below
5). Statistical analyses were performed with the statistical
package EpiInfo v5.00 (CDC, Atlanta, USA). Considering
our sample size and allelic frequencies, the statistical
power of our study to detect the influence of 1858C/T is
80% for an OR = 1.8 [8].
Family data were analyzed using the Transmission Dise-
quilibrium Test (TDT) [9]. Obviously, only information
from heterozygous parents was considered because only
in them we can differentiate between the transmitted and
non-transmitted allele.
Results
Allelic and genotypic frequencies for the case-control
study are shown in Table 1. Allelic frequencies in controls
are significantly different to those previously described in
other white populations (p = 0.0012, vs. North American
population and p = 0.0015 vs. Sardinian population
[10,11]), but previously reported frequencies also differ
significantly between them (p = 2.0*10-7 between North
American and Sardinian populations). PTPN22 1858C/T
allelic frequencies do not significantly differ between con-
trols and IgAD patients (p = 0.56). Statistically significant
differences were neither observed when carriage rate of T
allele was compared between patients and controls (p =
0.56).
Due to the known association of some HLA alleles with
IgAD, we also studied the association between PTPN22
and IgAD stratifying by carriage of DRB1*0102, DR3, DR3
and TNFa2b3, and for DR7, separately or combined, in
order to look for epistatic interactions between HLA-risk
factors and PTPN22. No statistically significant results
were obtained in any case. The family study also showed
negative results. Only 31 families included in this study
showed at least one heterozygous progenitor and could,
therefore, be used in the TDT. No significant preferential
transmission was observed for any of the alleles of this
gene, although a small trend was observed for the allele
1858C (allele C: 22 transmitted vs. 11 non-transmitted; p
= 0.08). Similar results were obtained when the data cor-
responding to the transmission from the mother and the
father were separately considered (data not shown).
Table 1: Genotype and allelic PTPN22 frequencies in patients (n 
= 259) and controls (n = 455).
IgAD patients (%) Controls (%)
Genotype
CC 225 (86.9) 402 (89.4)
CT 32 (12.3) 50 (11.0)
TT 2 (0.8) 3 (0.6)
Allele
C 482 (93.0) 854 (93.9)
T 36 (7.0) 56 (6.1)BMC Medical Genetics 2006, 7:25 http://www.biomedcentral.com/1471-2350/7/25
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Discussion
PTPN22 has been found associated with most autoim-
mune diseases studied so far, specifically with some of the
most prevalent ones, Graves disease, rheumatoid arthritis,
systemic lupus erythematosus and type 1 diabetes [6,10-
12]. This is the first study analyzing the involvement of
the PTPN22 gene in IgA deficiency. However, we could
not substantiate an association between PTPN22 and this
disease.
The association of several autoimmune diseases with the
PTPN22 1858C/T SNP has been considered as indicative
of the existence of an inflammatory process common to
many autoimmune diseases. According to this idea, the
lack of a positive association with that gene would sup-
port the non-autoimmune etiology of IgAD. Any defect in
some of the complex involved in T/B collaboration might
affect immunoglobulin production and therefore be
involved in the origin of IgAD. The consideration of IgAD
as an immunodeficiency, due to alterations in some proc-
ess involved in the production of IgA, is generally
accepted. However, it has been known for a long time that
immunodeficiencies and autoimmune processes occur
very often in the same individual [13,14]. As a matter of
fact, IgAD patients have autoimmune as well as immuno-
deficient features. However, perhaps one of those compo-
nents is developed secondarily to the other; thus the main
difficulty is to clarify which one comes first.
In view of our results we can not support firmly any
hypothesis, but it seems clear that at least IgAD is not a
conventional autoimmune disease, as shown by the lack
of association with PTPN22 1858T. This indirectly rein-
forces the original idea about the immunodeficient basis
of this disease. Of course, the lack of association with
PTPN22 is not as conclusive as a positive result, which
without doubt would have supported the autoimmune
nature of IgAD. Thus, one of the most important chal-
lenges for the future research on IgAD will be to clarify this
controversy.
Conclusion
No association between the 1858C/T SNP of the PTPN22
gene and IgA immunodeficiency has been found in a
Spanish population. This fact supports the primary immu-
nodeficient etiology of IgAD as opposed to an autoim-
mune basis.
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